Breaking News

Gallus, Omni Bio Enter Cell Line Manufacturing Pact

Aims to support toxicology studies and early clinical trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gallus BioPharmaceuticals and Omni Bio Pharmaceutical have finalized a multi-stage manufacturing agreement for cell line optimization, analytical development and scale-up for Omni Bio’s leading AAT Fc fusion protein. The goal is to provide cGMP product to support toxicology studies and early clinical trials.   Omni Bio has selected the CHOZNGS Cell line from SAFC as the expression system. SAFC will perform the cell line development and safety testing services, and Gallus will provide overall man...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters